Northern Trust Corp increased its holdings in shares of Lantheus Holdings Inc (NASDAQ:LNTH) by 0.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 475,961 shares of the medical equipment provider’s stock after buying an additional 2,723 shares during the quarter. Northern Trust Corp’s holdings in Lantheus were worth $7,448,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. PNC Financial Services Group Inc. raised its holdings in shares of Lantheus by 51.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,694 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 575 shares during the period. Financial Gravity Companies Inc. purchased a new position in shares of Lantheus in the 4th quarter worth about $45,000. Advisor Group Inc. raised its holdings in shares of Lantheus by 1,837.2% in the 4th quarter. Advisor Group Inc. now owns 4,378 shares of the medical equipment provider’s stock worth $69,000 after purchasing an additional 4,152 shares during the period. State of Alaska Department of Revenue raised its holdings in shares of Lantheus by 14.0% in the 4th quarter. State of Alaska Department of Revenue now owns 12,881 shares of the medical equipment provider’s stock worth $201,000 after purchasing an additional 1,580 shares during the period. Finally, GSA Capital Partners LLP purchased a new position in shares of Lantheus in the 4th quarter worth about $202,000. Hedge funds and other institutional investors own 93.34% of the company’s stock.
LNTH has been the topic of a number of research reports. BidaskClub upgraded Lantheus from a “buy” rating to a “strong-buy” rating in a report on Friday, February 22nd. Zacks Investment Research upgraded Lantheus from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a report on Wednesday, February 20th. ValuEngine downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, TheStreet upgraded Lantheus from a “c+” rating to a “b” rating in a report on Monday, March 4th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $23.33.
Shares of NASDAQ:LNTH opened at $25.25 on Tuesday. The stock has a market cap of $986.11 million, a P/E ratio of 26.86, a P/E/G ratio of 1.84 and a beta of 1.59. The company has a current ratio of 3.70, a quick ratio of 3.08 and a debt-to-equity ratio of 3.71. Lantheus Holdings Inc has a one year low of $12.59 and a one year high of $26.30.
Lantheus (NASDAQ:LNTH) last announced its earnings results on Tuesday, February 19th. The medical equipment provider reported $0.24 EPS for the quarter, beating the consensus estimate of $0.15 by $0.09. The business had revenue of $86.27 million for the quarter, compared to the consensus estimate of $83.93 million. Lantheus had a return on equity of 73.07% and a net margin of 11.80%. The company’s revenue was up 6.2% on a year-over-year basis. During the same period last year, the business posted $2.47 EPS. On average, equities analysts forecast that Lantheus Holdings Inc will post 1.15 earnings per share for the current year.
In related news, CEO Mary Anne Heino sold 9,564 shares of the firm’s stock in a transaction dated Wednesday, January 30th. The stock was sold at an average price of $16.47, for a total transaction of $157,519.08. Following the sale, the chief executive officer now directly owns 630,782 shares in the company, valued at approximately $10,388,979.54. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Cesare Orlandi sold 3,060 shares of the firm’s stock in a transaction dated Thursday, January 31st. The shares were sold at an average price of $16.56, for a total value of $50,673.60. Following the sale, the insider now owns 77,746 shares in the company, valued at $1,287,473.76. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 54,263 shares of company stock worth $1,172,220. Company insiders own 2.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first published by Macon Daily and is owned by of Macon Daily. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://macondaily.com/2019/04/16/lantheus-holdings-inc-lnth-position-boosted-by-northern-trust-corp.html.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.
Featured Article: What is the Bid-Ask Spread?
Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings Inc (NASDAQ:LNTH).
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.